Peter Braude
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Braude has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Susan J. Pickering
Department of Women's Health, GKT School of Medicine, 10th Floor, North Wing, St Thomas' Hospital, London SE1 7EH, UK
4 shared publications - Tarek El-Toukhy
Assisted Conception Unit, 11th Floor, Tower Wing, Guy's and St Thomas NHS Trust, London, UK
4 shared publications Yacoub Khalaf
3 shared publications- Chris Mason
The Advanced Centre for Biochemical Engineering, University College London, Torrington Place, London, WC1E 6BT, UK
2 shared publications - Emma L. Stephenson
Department of Women's Health and Division of Reproduction and Endocrinology, King's College London, London, UK
2 shared publications Frances Flinter
2 shared publications
Latest Publications
- Open Access
- 13 December 2020
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 128 (7) , 1171-1173
Transgenerational genomics: the profession should enhance its role as advocate for the health of the next generation
No profession should be more involved in the debate about Germline Genome Editing than the members of the Royal College of Obstetricians and Gynaecologists, the Royal College of Midwives, and the practitioners of new reproductive technologies, for the safety of future generations is in their hands. After all, it is our profession which has been the guardian of the health of the next generation and should continue to be so; this can only be achieved by embracing understanding of the new genomic technologies and by becoming involved in the discussions and decisions about their implementation.
- 13 December 2020
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 128 (7) , 1171-1173
Open AccessTransgenerational genomics: the profession should enhance its role as advocate for the health of the next generation
No profession should be more involved in the debate about Germline Genome Editing than the members of the Royal College of Obstetricians and Gynaecologists, the Royal College of Midwives, and the practitioners of new reproductive technologies, for the safety of future generations is in their hands. After all, it is our profession which has been the guardian of the health of the next generation and should continue to be so; this can only be achieved by embracing understanding of the new genomic technologies and by becoming involved in the discussions and decisions about their implementation.
- 20 November 2018
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 126 (2) , 135-137
Reflections on 40 years of IVF
- 20 November 2018
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 126 (2) , 135-137
Reflections on 40 years of IVF
- 1 August 2018
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 37 (2) , 133-135
The emperor still looks naked
- 1 August 2018
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 37 (2) , 133-135
The emperor still looks naked
- 1 December 2013
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 27 (6) , 644-653
Selecting the ‘best’ embryos: prospects for improvement
- 1 December 2013
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 27 (6) , 644-653
Selecting the ‘best’ embryos: prospects for improvement
- 1 November 2013
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 27 (5) , 570-572
Evidence-based medicine and the role of the private sector in assisted reproduction: a response to Dr Fishel’s commentary ‘Evidenced-based medicine and the role of the National Health Service in assisted reproduction’
- 1 November 2013
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 27 (5) , 570-572
Evidence-based medicine and the role of the private sector in assisted reproduction: a response to Dr Fishel’s commentary ‘Evidenced-based medicine and the role of the National Health Service in assisted reproduction’
- 2 October 2013
- Published by Springer Nature
- p. 211-220
The Future of Preimplantation Genetic Testing: From Research Lab to Responsible Patient Care
- 2 October 2013
- Published by Springer Nature
- p. 211-220
The Future of Preimplantation Genetic Testing: From Research Lab to Responsible Patient Care
Robert Edwards
Pioneer of in vitro fertilisation Bob Edwards was an extraordinarily gifted scientist. Few biologists have had such a positive and practical impact on the future of mankind through their basic research. For it was Bob, his clinical colleague Patrick Steptoe, and laboratory assistant Jean Purdy who in 1978 were to achieve the first birth after in vitro fertilisation (IVF),1 a technique that has brought joy to millions of previously infertile couples. Rather than a backroom boffin, Bob was immersed completely in the development of clinical progress through his deep understanding of reproductive biology and genetics, his prodigious knowledge of mammalian biology and animal husbandry,2 and his empathy for the plight of the “undeserving infertile.” The possibility that fertilisation could be manipulated or assisted in the laboratory had been mooted by the early experiments of Gregory Pincus, inventor of the oral contraceptive pill, and referred to in a prophetic 1937 editorial entitled “Conception in a watch glass.”3 Bob was passionate about the possibility that infertile couples could be helped by new techniques being developed in the laboratory, and exemplified …
Robert Edwards
Pioneer of in vitro fertilisation Bob Edwards was an extraordinarily gifted scientist. Few biologists have had such a positive and practical impact on the future of mankind through their basic research. For it was Bob, his clinical colleague Patrick Steptoe, and laboratory assistant Jean Purdy who in 1978 were to achieve the first birth after in vitro fertilisation (IVF),1 a technique that has brought joy to millions of previously infertile couples. Rather than a backroom boffin, Bob was immersed completely in the development of clinical progress through his deep understanding of reproductive biology and genetics, his prodigious knowledge of mammalian biology and animal husbandry,2 and his empathy for the plight of the “undeserving infertile.” The possibility that fertilisation could be manipulated or assisted in the laboratory had been mooted by the early experiments of Gregory Pincus, inventor of the oral contraceptive pill, and referred to in a prophetic 1937 editorial entitled “Conception in a watch glass.”3 Bob was passionate about the possibility that infertile couples could be helped by new techniques being developed in the laboratory, and exemplified …
- 1 January 2012
- Published by Elsevier
Contributor contact details
- 17 November 2011
- Published by Taylor & Francis in Human Fertility
- Vol. 14 (4) , 224-229
Viral screening before each cycle of assisted conception treatment is expensive and unnecessary: a survey of results from a UK inner city clinic
The European Union Tissues and Cells Directive requires screening of tissue and cell donors for infective organisms to prevent inter-patient transmission. The Directive includes the unique term partner donation, which refers to "donation of reproductive cells between a man and a woman who declare that they have an intimate physical relationship". In line with the Directive, partners undergoing Assisted Reproductive Technology (ART) now require screening before each treatment, regardless of the time interval between consecutive cycles. Evidence to support this recommendation is lacking. Therefore, we conducted a retrospective study of all virology screening tests undertaken over a three year period for individuals attending an assisted conception unit serving a high risk inner city population. We ascertained prevalence and seroconversion rates for HIV, hepatitis B and C and estimated the additional cost of implementing the Directive fully in our unit. With more than 3910 ART individuals screened between January 2007 and December 2009, the prevalence of HIV, hepatitis B and C was 0.6, 1.7 and 0.4%, respectively. A total of 422 individuals had a second screening test during the three year period and none seroconverted. This study suggests that increasing the frequency of screening individuals undergoing ART to less than 12 months would not confer added benefit and has significant cost implications.
- 17 November 2011
- Published by Taylor & Francis in Human Fertility
- Vol. 14 (4) , 224-229
Viral screening before each cycle of assisted conception treatment is expensive and unnecessary: a survey of results from a UK inner city clinic
The European Union Tissues and Cells Directive requires screening of tissue and cell donors for infective organisms to prevent inter-patient transmission. The Directive includes the unique term partner donation, which refers to "donation of reproductive cells between a man and a woman who declare that they have an intimate physical relationship". In line with the Directive, partners undergoing Assisted Reproductive Technology (ART) now require screening before each treatment, regardless of the time interval between consecutive cycles. Evidence to support this recommendation is lacking. Therefore, we conducted a retrospective study of all virology screening tests undertaken over a three year period for individuals attending an assisted conception unit serving a high risk inner city population. We ascertained prevalence and seroconversion rates for HIV, hepatitis B and C and estimated the additional cost of implementing the Directive fully in our unit. With more than 3910 ART individuals screened between January 2007 and December 2009, the prevalence of HIV, hepatitis B and C was 0.6, 1.7 and 0.4%, respectively. A total of 422 individuals had a second screening test during the three year period and none seroconverted. This study suggests that increasing the frequency of screening individuals undergoing ART to less than 12 months would not confer added benefit and has significant cost implications.